SNOA Stock Overview
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally.
Sonoma Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.27|
|52 Week High||US$7.20|
|52 Week Low||US$2.06|
|1 Month Change||-18.14%|
|3 Month Change||-23.57%|
|1 Year Change||-58.43%|
|3 Year Change||-54.96%|
|5 Year Change||-94.67%|
|Change since IPO||-99.91%|
Recent News & Updates
Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99M
Sonoma Pharmaceuticals press release (NASDAQ:SNOA): Q1 GAAP EPS of -$0.29. Revenue of $3.99M (+8.4% Y/Y).
|SNOA||US Pharmaceuticals||US Market|
Return vs Industry: SNOA underperformed the US Pharmaceuticals industry which returned 6.2% over the past year.
Return vs Market: SNOA underperformed the US Market which returned -18.8% over the past year.
|SNOA Average Weekly Movement||9.6%|
|Pharmaceuticals Industry Average Movement||11.3%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: SNOA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: SNOA's weekly volatility (10%) has been stable over the past year.
About the Company
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds.
Sonoma Pharmaceuticals Fundamentals Summary
|SNOA fundamental statistics|
Is SNOA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SNOA income statement (TTM)|
|Cost of Revenue||US$8.94m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.57|
|Net Profit Margin||-37.71%|
How did SNOA perform over the long term?See historical performance and comparison
Is SNOA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SNOA?
Other financial metrics that can be useful for relative valuation.
|What is SNOA's n/a Ratio?|
Price to Sales Ratio vs Peers
How does SNOA's PS Ratio compare to its peers?
|SNOA PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
CPHI China Pharma Holdings
EMMA Emmaus Life Sciences
NBY NovaBay Pharmaceuticals
GPFT Grapefruit USA
SNOA Sonoma Pharmaceuticals
Price-To-Sales vs Peers: SNOA is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (7.2x).
Price to Earnings Ratio vs Industry
How does SNOA's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: SNOA is good value based on its Price-To-Sales Ratio (0.5x) compared to the US Pharmaceuticals industry average (3x)
Price to Sales Ratio vs Fair Ratio
What is SNOA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.5x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate SNOA's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of SNOA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SNOA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SNOA's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Sonoma Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sonoma Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Sonoma Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
How has Sonoma Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SNOA is currently unprofitable.
Growing Profit Margin: SNOA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SNOA is unprofitable, but has reduced losses over the past 5 years at a rate of 25.1% per year.
Accelerating Growth: Unable to compare SNOA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SNOA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).
Return on Equity
High ROE: SNOA has a negative Return on Equity (-61.25%), as it is currently unprofitable.
Discover strong past performing companies
How is Sonoma Pharmaceuticals's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SNOA's short term assets ($14.8M) exceed its short term liabilities ($4.9M).
Long Term Liabilities: SNOA's short term assets ($14.8M) exceed its long term liabilities ($4.3M).
Debt to Equity History and Analysis
Debt Level: SNOA has more cash than its total debt.
Reducing Debt: SNOA's debt to equity ratio has increased from 0.7% to 6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SNOA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SNOA has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.7% each year.
Discover healthy companies
What is Sonoma Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Sonoma Pharmaceuticals Dividend Yield vs Market|
|Company (Sonoma Pharmaceuticals)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Pharmaceuticals)||2.6%|
|Analyst forecast in 3 Years (Sonoma Pharmaceuticals)||n/a|
Notable Dividend: Unable to evaluate SNOA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SNOA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SNOA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SNOA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SNOA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Amy Trombly (54 yo)
Ms. Amy M. Trombly, Esq. has been Chief Executive Officer of Sonoma Pharmaceuticals, Inc. since September 25, 2019 and serves as its President and also serves as its Director since July 22, 2022. She is a...
CEO Compensation Analysis
|Amy Trombly's Compensation vs Sonoma Pharmaceuticals Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||US$621k||US$300k|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||US$386k||US$153k|
Compensation vs Market: Insufficient data to establish whether Amy's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Amy's compensation has increased whilst the company is unprofitable.
Experienced Management: SNOA's management team is considered experienced (2.5 years average tenure).
Experienced Board: SNOA's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.2%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Sonoma Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Sonoma Pharmaceuticals, Inc.
- Ticker: SNOA
- Exchange: NasdaqCM
- Founded: 1999
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$7.039m
- Shares outstanding: 3.10m
- Website: https://www.sonomapharma.com
Number of Employees
- Sonoma Pharmaceuticals, Inc.
- 645 Molly Lane
- Suite 150
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SNOA||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Jan 2007|
|O8Z3||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 2007|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/06 00:00|
|End of Day Share Price||2022/10/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.